November 6, 2024 07:00 AM EST

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Kyle LaHucik

Senior Reporter

SAN ANTONIO — It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field’s next …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

New Trump era could be a boon for biopharma M&A, dealmaking

Acadia lands $150M sale of rare pediatric PRV

Novo unveils new cardiometabolic data as it reports solid third-quarter profits

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs